Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883004 | 0.83 | HSP90AA1 (0.37) | HSP90AA1P2RX7HKDC1GRM5DUSP3 | |
| SCHEMBL882894 | 0.77 | HSP90AA1 (0.38) | HSP90AA1P2RX7HKDC1GRM5DUSP3 | |
| SCHEMBL10273807 | 0.76 | HSP90AA1 (0.37) | HSP90AA1P2RX7HKDC1GRM5DUSP3 | |
| SCHEMBL10273699 | 0.74 | HSP90AA1 (0.36) | HSP90AA1P2RX7HKDC1DUSP3PTPN11 | |
| SCHEMBL882636 | 0.73 | HSP90AA1 (0.43) | HSP90AA1P2RX7HKDC1GRM5DUSP3 | |
| SCHEMBL16164505 | 0.73 | HSP90AA1 (0.43) | HSP90AA1P2RX7HKDC1GRM5DUSP3 | |
| SCHEMBL19089529 | 0.73 | CYP1A2 (0.38) | HSP90AA1MEN1KMT2A | |
| SCHEMBL883002 | 0.73 | P2RX7 (0.39) | HSP90AA1P2RX7HKDC1GRM5DUSP3 | |
| SCHEMBL882654 | 0.71 | NPC1 (0.32) | HSP90AA1 | |
| SCHEMBL874106 | 0.71 | P2RX7 (0.41) | HSP90AA1P2RX7HKDC1GRM5DUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | MSR1, C3AR1, CD209 | HSP90AA1 2350/4885P2RX7 630/4885HKDC1 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.